Should I Buy MGX? MGX 2026 Analysis

Should You Buy Metagenomi Therapeutics Inc (MGX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.600

1 Day change

-3.61%

52 Week Range

3.950

Analysis Updated At

2026/01/26

Metagenomi Therapeutics Inc (MGX) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, bearish technical indicators, and a lack of positive catalysts. While the company has a 'Buy' rating from analysts, the lowered price target and hedge fund selling suggest caution. Given the investor's scenario and the absence of strong trading signals, holding off on this stock is recommended.

Technical Analysis

The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 48.992, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.707, with support at 1.623 and resistance at 1.791. Overall, the technical indicators suggest a bearish trend.

Options Data

Positive Catalysts

The appointment of Dr. Jian Irish as CEO and updated preclinical data on MGX-001 in hemophilia A could be seen as potential long-term catalysts.

Neutral/Negative Catalysts

Hedge funds are selling heavily, with a 323.12% increase in selling activity last quarter. Analysts have lowered the price target from $11 to $7, and the majority of platform value has been removed from the model.

Financial Performance

In Q3 2025, revenue dropped to $8,659,000 (-24.80% YoY). Net income improved slightly to -$20,393,000 (+8.63% YoY), and EPS increased to -0.55 (+7.84% YoY). Gross margin remained flat at 100%. Overall, the financial performance shows weak growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Chardan analyst Geulah Livshits maintains a 'Buy' rating but lowered the price target from $11 to $7 due to Q3 financials and prioritization of resources. This reflects a cautious outlook despite the positive rating.

4 Analyst Rating

Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.660

Low

Averages

8.67

High

Current: 1.660

Low

Averages

8.67

High

Chardan

Geulah Livshits

Buy

downgrade

$11 -> $7

AI Analysis

2025-11-12

Reason

Chardan

Geulah Livshits

Price Target

$11 -> $7

AI Analysis

2025-11-12

downgrade

Buy

Reason

Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.

Chardan

downgrade

$12 -> $11

2025-08-15

Reason

Chardan

Price Target

$12 -> $11

2025-08-15

downgrade

Reason

Chardan lowered the firm's price target on Metagenomi to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGX

Unlock Now

MGX Should I Buy

MGX Should I Buy

Should You Buy Metagenomi Therapeutics Inc (MGX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch